Mason Lorna, Edwards Jayne E, Moore R Andrew, McQuay Henry J
Pain Research and the Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospital, The Churchill, Headington, Oxford, OX3 7LJ, UK.
BMC Anesthesiol. 2003 Sep 10;3(1):4. doi: 10.1186/1471-2253-3-4.
Naproxen and naproxen sodium are non-steroidal anti-inflammatory drugs used in a variety of painful conditions, including the treatment of postoperative pain. This review aims to assess the efficacy, safety and duration of action of a single oral dose of naproxen/naproxen sodium for moderate to severe acute postoperative pain in adults, compared with placebo. METHODS: The Cochrane Library (issue 4 2002), EMBASE, PubMed, MEDLINE and an in-house database were searched for randomised, double blind, placebo controlled trials of a single dose of orally administered naproxen or naproxen sodium in adults with acute postoperative pain. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of patients with at least 50% pain relief over 4 to 6 hours. Relative benefit and number-needed-to-treat were then calculated. The percentage of patients with any adverse event, number-needed-to-harm, and time to remedication were also calculated. RESULTS: Ten trials with 996 patients in met the inclusion criteria. Six trials compared naproxen sodium 550 mg (252 patients) with placebo (248 patients); the NNT for at least 50% pain relief over six hours was 2.6 (95% confidence interval 2.2 to 3.2). There was no significant difference between the number of patients experiencing any adverse event on treatment compared with placebo. Weighted mean time to remedication was 7.6 hours for naproxen sodium 550 mg (206 patients) and 2.6 hours for placebo (205 patients). Four other trials used lower doses. CONCLUSION: A single oral dose of naproxen sodium 550 mg is an effective analgesic in the treatment of acute postoperative pain. A low incidence of adverse events was found, although these were not reported consistently.
萘普生和萘普生钠是非甾体抗炎药,用于多种疼痛状况,包括术后疼痛的治疗。本综述旨在评估单剂量口服萘普生/萘普生钠用于成人中度至重度急性术后疼痛的疗效、安全性和作用持续时间,并与安慰剂进行比较。
检索考克兰图书馆(2002年第4期)、EMBASE、PubMed、MEDLINE以及一个内部数据库,查找关于单剂量口服萘普生或萘普生钠用于急性术后疼痛成人的随机、双盲、安慰剂对照试验。提取疼痛缓解或疼痛强度数据,并转化为二分信息,以得出在4至6小时内疼痛缓解至少50%的患者数量。然后计算相对获益和需治疗人数。还计算了发生任何不良事件的患者百分比、需伤害人数以及再次用药时间。
10项试验共996例患者符合纳入标准。6项试验比较了550毫克萘普生钠(252例患者)与安慰剂(248例患者);6小时内疼痛缓解至少50%的需治疗人数为2.6(95%置信区间2.2至3.2)。与安慰剂相比,治疗中发生任何不良事件的患者数量无显著差异。550毫克萘普生钠(206例患者)再次用药的加权平均时间为7.6小时,安慰剂(205例患者)为2.6小时。其他4项试验使用了较低剂量。
单剂量口服550毫克萘普生钠是治疗急性术后疼痛的有效镇痛药。不良事件发生率较低,尽管报告并不一致。